

Wholesale Acquisition Cost Information for Colorado Prescribers of Prescription Drugs

MARGENZA® (margetuximab-cmkb)

In accordance with the Colorado Wholesale Acquisition Cost Disclosure Law (Colorado Revised Statutes Section 12-42.5-308), TerSera Therapeutics LLC (“TerSera”) is disclosing, in writing, to authorized prescribers of prescription drugs in Colorado certain required wholesale acquisition cost (“WAC”) pricing information for TerSera-marketed products. The information provided is administrative only and makes no claims of efficacy or safety about any product listed. This disclosure provides the WAC price for the product(s) listed below.

Marketed Product:

| NDC | TerSera Product | Dosage Form | Strength | Unit Size | Wholesale Acquisition Cost* |
|---------------|---------------------------------|--------------------------------|------------|---------------------|-----------------------------|
| 74527-0022-02 | MARGENZA (margetuximab-cmkb) | Injection, for intravenous use | 250mg/10mL | 1-vial in 1 carton | \$2,874.21 |
| 74527-0022-03 | MARGENZA (margetuximab-cmkb) | Injection, for intravenous use | 250mg/10mL | 4-vials in 1 carton | \$11,496.84 |

Generic Products:**

None

*Pricing as of 06 April 2026. The pricing information disclosed above represents the WAC price, which represents the manufacturer’s published catalog or list price for a drug product to wholesalers as reported to third-party drug pricing publishers. WAC does not represent actual transaction prices and does not include discounts, rebates, or reductions in price. The price paid by consumers may differ significantly from the WAC listed.

**This listing of generic drugs does not imply that the products are interchangeable with the TerSera-marketed product or have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information. To access approved prescribing information for TerSera-marketed products, visit <https://tersera.com/our-medicines>.

The Colorado Wholesale Acquisition Cost Disclosure Law requires disclosure of up to three generic products, if any, in the same “therapeutics class” as the marketed products. Colorado defines “therapeutics class” as “a group of similar drugs that have the same or similar mechanisms of action and are used to treat a specific condition”.